Patients presenting with chest pain and shortness of breath are time-critical emergencies that leave your lab no room for error or delay in completing cardiac diagnostic tests. Achieving the best patient outcomes requires the fastest intervention possible.
Exceptional assay performance to inform treatment decisions
Our ValuMetrix® services team has proven results: one STAT lab increased testing volume by 82.6% without adversely impacting turnaround time.
*China ValuCheck® report. Data on file.
Don't waste time waiting: with a 24-hour ready mode, VITROS® Systems are ready when you are, with no ramp-up time.
Learn how VITROS® Automation Solutions can drive faster turnaround time, improved safety and a reduction in staffing requirements.
Our assays are designed to consistently produce accurate results – the first time – so your lab can reduce errors, deliver quality results and help clinicians set the course for quality patient care.
VITROS® Troponin I ES Assay
Assay sensitivity and precision deliver reliable short-term and long-term risk information for patients with acute coronary syndrome.
VITROS Troponin I ES Assay
- Demonstrated comparable diagnostic performance to two well-validated high-sensitivity troponin assays in an assay comparison study1
- Described as a sensitive, contemporary assay in the literature with precision equal to 10% CV at the 99th percentile URL2
- Meets the precision requirement for an assay to be designated as high sensitivity3
- Current AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain states cardiac troponin (I or T) is the preferred biomarker to detect or exclude cardiac injury because of its high sensitivity and specificity for myocardial tissue.4
- The guideline recommends using troponin assays with a total coefficient of variation (CV) ≤10% at the 99th percentile URL4
- VITROS troponin I ES assay and all high-sensitivity troponin assays meet the guideline-recommended CV at the 99th percentile URL.
- The guideline does not state only high-sensitivity troponin assays must be used to aid in the diagnosis of acute myocardial infarction.
- Hemolysis, icterus and turbidity (HIT) interferences are automatically detected with VITROS MicroSensor technology on every sample in less than one second, without the use of any additional sample
1. Chenevier-Gobeaux C, Deweerdt L, Cantero A-V, et al. Multi-centre evaluation of recent troponin assays for the diagnosis of NSTEMI. Practical Laboratory Medicine. 2018;11:23-32. doi:10.1016/j.plabm.2018.02.003
2. Sandoval Y, Thordsen SE, Smith SW, et al. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J Acute Cardiovasc Care. 2014;3(4):317-325. Doi:10.1177/2048872614538411
3. Wu AHB, Christenson RH, Greene DN, et al. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018;64(4):645-655. doi:10.1373/clinchem.2017.277186
4. Writing Committee Members, Gulati M, Levy PD, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Cardiovasc Comput Tomogr. 2022;16(1):54-122. doi:10.1016/j.jcct.2021.11.009
VITROS® NT-proBNP II Assay
NT-proBNP II is more stable than BNP, an important feature when samples must be transported.1
VITROS NT-proBNP II assay:
Validated for use with ICON age-specific cutoffs1, which optimize diagnosis decisions, accounting for age and renal function with better specificity of acute dyspnea cases2-6
Long calibration interval at 70 days
Automated, on-the-fly loading of consumables and reagents with no interruptions
Intelligent sampling order to balance processing demands
Correlates well with most other NT-proBNP assays5
1. Daniels LB, Ajongwen P, Christenson RH, et al. Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis. J Appl Lab Med. 2025;10(2):325-338. doi:10.1093/jalm/jfae107
2.Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-2019. doi:10.1161/CIRCULATIONAHA.110.979500
3. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; 52(8):1528-1538. doi:10.1373/clinchem.2006.069575
5. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.032
5. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J. 2006;27(3):330-337. doi:10.1093/eurheartj/ehi631
6. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670. doi:10.1016/j.jchf.2014.09.001
VITROS® cardiac assay menu
Related products
